



ASX ANNOUNCEMENT

16 December 2024

Updated 3y – Antanas Guoga

Melbourne, Australia – Opyl Limited (ASX: OPL), refers to the Appendix 3Y dated 13 December 2024. The updated 3y attached today includes the 440,000 unlisted options expiring 10/12/2024 the subject of the cessation of the 2,335,000 options as disclosed by OPL to the market on 13 December 2024.

This announcement has been authorised for release by the board

-ENDS-

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice@trialkey.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Opyl Limited
ABN	71 063 144 865

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Antanas Guoga
Date of last notice	2 August 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	11 December 2024
No. of securities held prior to change	(1) 440,000 - UNLISTED OP EXP 10/12/24 @ \$0.80 (2) 5,833,333 - UNLISTED OP EX 01/12/2026 @ \$0.03 (3) 300,000 - UNLISTED OP EX 01/12/2028 (100,000 @ \$0.05, 100,000 @ \$0.075, 100,000@\$0.10) (4) 23,624,949 - ORDINARY FULLY PAID SHARES
Class	ORDINARY FULLY PAID SHARES
Number acquired	1,500,000 - ORDINARY FULLY PAID SHARES
Number disposed	Nil - 440,000 - UNLISTED OP EXP 10/12/24 @ \$0.80 have expired
Value/Consideration	\$0.03 per Share
No. of securities held after change	(1) 5,833,333 - UNLISTED OP EX 01/12/2026 @ \$0.03 (2) 300,000 - UNLISTED OP EX 01/12/2028 (100,000 @ \$0.05, 100,000 @ \$0.075, 100,000@\$0.10) (3) 25,124,949 - ORDINARY FULLY PAID SHARES
Nature of change	On market trade and option expiry

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Appendix 3Y
Change of Director's Interest Notice

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺ Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A